{"id":823215,"date":"2026-07-03T10:20:03","date_gmt":"2026-07-03T10:20:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=823215"},"modified":"2026-07-03T10:20:03","modified_gmt":"2026-07-03T10:20:03","slug":"mesothelioma-pipeline-2026-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-gsk-merck-bristolmyers-squibb-astrazeneca-roche-novartis-pfizer-inc","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/mesothelioma-pipeline-2026-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-gsk-merck-bristolmyers-squibb-astrazeneca-roche-novartis-pfizer-inc_823215.html","title":{"rendered":"Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/07\/1783014579.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/07\/1783014579.jpg\" alt=\"Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas, Nevada, United States)  As per DelveInsight\u2019s assessment, globally, Mesothelioma pipeline constitutes 45+ key companies continuously working towards developing 50+ Mesothelioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Mesothelioma Pipeline Insight, 2026<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mesothelioma Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Mesothelioma Pipeline Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Companies across the globe are diligently working toward developing novel Mesothelioma treatment therapies with a considerable amount of success over the years.<\/p>\n<\/li>\n<li>\n<p>Mesothelioma companies working in the treatment market are T<strong>he Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, &Aring;slaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others,<\/strong> are developing therapies for the Mesothelioma treatment<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Emerging Mesothelioma therapies in the different phases of clinical trials are- <strong>Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others<\/strong> are expected to have a significant impact on the Mesothelioma market in the coming years.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2026, Researchers<\/strong> continued enrolling patients in clinical trials evaluating mesothelin-targeted CAR-T cell therapies, bispecific antibodies, and personalized immunotherapy strategies aimed at enhancing treatment outcomes for individuals with advanced mesothelioma.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2026, The ATOMIC-Meso trial<\/strong> assessed the efficacy of weekly intramuscular pegargiminase in combination with pemetrexed and platinum-based chemotherapy compared with placebo plus chemotherapy in previously untreated patients with mesothelioma. The study represents one of the most advanced late-stage clinical development programs for the disease.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Multiple Phase I&ndash;III clinical trials<\/strong> investigating immunotherapies, targeted therapies, CAR-T cell therapies, and tumor-targeted agents continued to enroll patients with malignant pleural mesothelioma, reflecting sustained progress in the disease&#8217;s therapeutic pipeline.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2025, VT3989,<\/strong> a TEAD autopalmitoylation inhibitor, has been granted orphan drug designation by the FDA for treating adult mesothelioma patients, as announced by Vivace Therapeutics.<\/p>\n<\/li>\n<li>\n<p><strong>In July 2025, The U.S. FDA<\/strong> has awarded orphan drug designation to VT3989 for mesothelioma treatment in the United States, according to Vivace Therapeutics. VT3989 is an investigational therapy that inhibits palmitoylation in TEAD proteins, key components of the Hippo pathway, which regulates cell growth and division.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2025, GSK&rsquo;s Zejula (niraparib<\/strong>) demonstrated a 27% reduction in the risk of disease progression or death in mesothelioma patients in an investigator-initiated Phase II trial. The NERO study (NCT05455424) evaluated Zejula&rsquo;s effectiveness in 88 mesothelioma patients who experienced relapse following prior platinum-based systemic therapy. The trial is sponsored by the University Hospital Southampton NHS Foundation Trust and funded by Asthma + Lung UK, with additional support from Mesothelioma UK and the Mavis Nye Foundation.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2025, Insilico Medicine (&#8220;Insilico&#8221;),<\/strong> a clinical-stage AI-driven biotechnology company, has announced that the first patient has been dosed in its global multicenter Phase I trial of ISM6331, a novel pan-TEAD inhibitor developed using its AI-powered generative chemistry platform, Chemistry42. ISM6331 is being investigated for the treatment of mesothelioma and other solid tumors. Notably, it is Insilico&rsquo;s leading oncology program within its AI-driven drug discovery pipeline and has received Orphan Drug Designation (ODD) from the FDA for mesothelioma treatment.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (mesothelium). The most common form is pleural mesothelioma, which affects the lining of the lungs and is often associated with exposure to asbestos fibers. Other less common forms include peritoneal mesothelioma (affecting the lining of the abdomen), and pericardial mesothelioma (affecting the lining around the heart).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Mesothelioma Pipeline Therapeutic Assessment-<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">https:\/\/www.delveinsight.com\/report-store\/mesothelioma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Mesothelioma Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Pembrolizumab:<\/strong> The Netherlands Cancer Institute<\/p>\n<\/li>\n<li>\n<p><strong>Nivolumab:<\/strong> Bristol-Myers Squibb<\/p>\n<\/li>\n<li>\n<p><strong>Durvalumab:<\/strong> PrECOG, LLC.<\/p>\n<\/li>\n<li>\n<p><strong>Sacituzumab govitecan-hziy:<\/strong> Memorial Sloan Kettering Cancer Center<\/p>\n<\/li>\n<li>\n<p><strong>Carboplatin:<\/strong> ETOP IBCSG Partners Foundation<\/p>\n<\/li>\n<li>\n<p><strong>Tremelimumab:<\/strong> MedImmune LLC<\/p>\n<\/li>\n<li>\n<p><strong>ipilimumab:<\/strong> &Aring;slaug Helland<\/p>\n<\/li>\n<li>\n<p><strong>Volrustomig:<\/strong> AstraZeneca<\/p>\n<\/li>\n<li>\n<p><strong>OT-101:<\/strong> Oncotelic Inc.<\/p>\n<\/li>\n<li>\n<p><strong>Lenvatinib:<\/strong> Hyogo Medical University<\/p>\n<\/li>\n<li>\n<p><strong>rAd-IFN:<\/strong> Trizell Ltd<\/p>\n<\/li>\n<li>\n<p><strong>RSO-021:<\/strong> RS Oncology LLC<\/p>\n<\/li>\n<li>\n<p><strong>VT3989:<\/strong> Vivace Therapeutics, Inc<\/p>\n<\/li>\n<li>\n<p><strong>gavo-cel:<\/strong> TCR2 Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>THOR-707:<\/strong> Sanofi<\/p>\n<\/li>\n<li>\n<p><strong>T3011:<\/strong> ImmVira Pharma Co. Ltd<\/p>\n<\/li>\n<li>\n<p><strong>TC-510:<\/strong> TCR2 Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>CTX131:<\/strong> CRISPR Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>PM8002:<\/strong> Biotheus Inc.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Mesothelioma Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Recombinant fusion proteins<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Monoclonal antibody<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<li>\n<p>Polymer<\/p>\n<\/li>\n<li>\n<p>Gene therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Mesothelioma Assessment by Product Type<\/p>\n<\/li>\n<li>\n<p>Mesothelioma By Stage and Product Type<\/p>\n<\/li>\n<li>\n<p>Mesothelioma Assessment by Route of Administration<\/p>\n<\/li>\n<li>\n<p>Mesothelioma By Stage and Route of Administration<\/p>\n<\/li>\n<li>\n<p>Mesothelioma Assessment by Molecule Type<\/p>\n<\/li>\n<li>\n<p>Mesothelioma by Stage and Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Mesothelioma Report covers around 50+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late-stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<li>\n<p>Route of Administration<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Mesothelioma product details are provided in the report. Download the Mesothelioma pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">emerging Mesothelioma therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Mesothelioma Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies developing therapies for Mesothelioma are &#8211; <em><strong>Merck &amp; Co., Inc., Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, Johnson &amp; Johnson, GlaxoSmithKline plc (GSK), AbbVie Inc., Sanofi, and others.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Pipeline Analysis:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Mesothelioma pipeline report provides insights into<\/p>\n<\/li>\n<li>\n<p>The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li>\n<p>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.<\/p>\n<\/li>\n<li>\n<p>Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Mesothelioma drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Rising incidence of malignant pleural mesothelioma due to historical asbestos exposure worldwide.<\/p>\n<\/li>\n<li>\n<p>Increasing focus on immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapies, and mesothelin-targeted treatments.<\/p>\n<\/li>\n<li>\n<p>Strong pipeline of targeted therapies, gene therapies, and personalized medicine approaches aimed at improving patient outcomes.<\/p>\n<\/li>\n<li>\n<p>Growing number of clinical trials supported by regulatory incentives such as Orphan Drug, Fast Track, and Breakthrough Therapy designations.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Low disease prevalence limits patient recruitment and slows clinical trial enrollment.<\/p>\n<\/li>\n<li>\n<p>Late-stage diagnosis and aggressive disease progression reduce the treatment window and clinical trial participation.<\/p>\n<\/li>\n<li>\n<p>High development costs and lengthy clinical timelines for rare oncology therapies.<\/p>\n<\/li>\n<li>\n<p>Limited understanding of mesothelioma biology and tumor heterogeneity complicates drug development.<\/p>\n<\/li>\n<li>\n<p>Difficulty demonstrating significant survival benefits in clinical studies due to small patient populations.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Mesothelioma Pipeline Drug Insight <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Coverage: Global<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Key Mesothelioma Companies:<\/strong> The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, &Aring;slaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Mesothelioma Therapies:<\/strong> Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others<\/p>\n<\/li>\n<li>\n<p><strong>Mesothelioma Therapeutic Assessment:<\/strong> Mesothelioma current marketed and Mesothelioma emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Mesothelioma Market Dynamics: Mesothelioma market drivers and Mesothelioma market barriers <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Mesothelioma Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Mesothelioma Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Mesothelioma Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Mesothelioma Overview<\/p>\n<p style=\"text-align: justify;\">4. Mesothelioma- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. Mesothelioma Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. Mesothelioma Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify;\">7. Mesothelioma Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">8. Mesothelioma Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">9. Mesothelioma Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Mesothelioma Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Mesothelioma Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Mesothelioma Key Companies<\/p>\n<p style=\"text-align: justify;\">14. Mesothelioma Key Products<\/p>\n<p style=\"text-align: justify;\">15. Mesothelioma Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16 . Mesothelioma Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Mesothelioma Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Mesothelioma Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=mesothelioma-pipeline-2026-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-gsk-merck-bristolmyers-squibb-astrazeneca-roche-novartis-pfizer-inc\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679  Source: https:\/\/www.delveinsight.com\/report-store.php<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=mesothelioma-pipeline-2026-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-gsk-merck-bristolmyers-squibb-astrazeneca-roche-novartis-pfizer-inc\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Las Vegas, Nevada, United States) As per DelveInsight\u2019s assessment, globally, Mesothelioma pipeline constitutes 45+ key companies continuously working towards developing 50+ Mesothelioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. &nbsp; &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/mesothelioma-pipeline-2026-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-gsk-merck-bristolmyers-squibb-astrazeneca-roche-novartis-pfizer-inc_823215.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-823215","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/823215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=823215"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/823215\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=823215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=823215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=823215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}